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The current pandemic in obesity/metabolic syndrome is 
a   risk  factor  for  many  types  of   diseases,  including  
 
 

















































cancer. In up to 90% of cases, obesity is accompanied 
by non-alcoholic-fatty-liver-disease (NAFLD) [1]. 
NAFLD is the consequence of an imbalance between 
lipid availability through fatty acid (FA) uptake and de 

































are  generally  deteriorated  during  the  aging  process.  MacroH2A1,  a  variant  of  histone  H2A,  is  a  key  transcriptional




are differentially expressed  in mice models of NAFLD. Here we  show  that over‐expression of macroH2A1.1, but not of
macroH2A1.2,  is  able  to  protect  hepatocytes  against  lipid  accumulation.  MacroH2A1.1  over‐expressing  cells  display
ameliorated glucose metabolism,  reduced expression of  lipidogenic genes and  fatty acids  content. SIRT1/macroH2A1.1‐
dependent epigenetic regulation of lipid metabolism may be relevant to NAFLD development.  
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novo lipogenesis, and lipid secretion and disposal via 
free fatty acid (FFA) oxidation, resulting in hepatic 
steatosis [2]. In 10% of the cases NAFLD will progress 
to steatohepatitis (NASH), and in 8-26% to cirrhosis, 
with an increasing incidence of cases with NAFLD that 
develop hepatocellular carcinoma (HCC) at an earlier 
stage [3]. There is substantial evidence that the 
progression from NAFLD to HCC is accrued by the 
aging process [4]. Epigenetic mechanisms of nuclear 
chromatin remodelling, such as DNA methylation, post-
translational modifications of histones, and 
incorporation of histone variants into the chromatin are 
increasingly recognized as crucial factors in the 
pathophysiology of NAFLD and in several age-
associated  diseases [5-7]. In fact, alterations in hepatic 
metabolism and proliferation during steatosis are 
triggered by changes in gene transcriptional patterns 
dependent on the degree of nuclear chromatin 
compaction. The latter is regulated at several levels, 
allowing transcriptional plasticity [8]: one way is the 
replacement of canonical histones around which DNA 
is wrapped (H2A, H2B, H3 and H4) with the 
incorporation of histone variants. The histone variant of 
H2A, known as macroH2A1, is believed to act as a 
strong transcriptional modulator that can either repress 
transcription [9, 10], or activate it in response to as yet 
undefined growth signals [11]. The phenotype of 
macroH2A1 knock out (KO) mice consists of mild and 
variable derangements in systemic and/or hepatic 
glucose and lipid metabolism, depending on the strain 
[12, 13]. MacroH2A1 is present in 2 isoforms, 
macroH2A1.1 and macroH2A1.2, which are generated 
upon RNA alternative exon splicing (Figure 1A). These 
isoforms differ in just few amino acids, a conserved 
structural difference that explains why macroH2A1.1 
can bind ADP-ribose-like metabolites produced by 
NAD+-dependent histone deacetylase SIRT1, such as 
O-acetyl ADP ribose (OAADPR), or by polyADP-
ribose polymerase 1 (PARP1), while macroH2A1.2 is 
unable to do so [14-17]. Interestingly, this binding was 
the first described direct molecular interaction between 
intermediate metabolism and the chromatin, whereby a 
metabolite can impinge on and tweak gene expression 
[14-16]. MacroH2A1 isoforms regulate cancer cell 
growth in vitro [18] and their expression levels have 
been shown to mark HCC, colon and lung cancer 
recurrence [19-21]. MacroH2A1 isoforms accumulate 
massively in the nuclei of senescent hepatocyte and 
fibroblasts, although the functional significance of this 
finding is unknown [19, 22]. Moreover, KO of all 
macroH2A1 isoforms induced the progression of the 
malignant phenotype of melanoma through increased 
expression of CDK8 oncogene [23]. The epigenetic 
regulation of oncogenes and/or tumor suppressors is 
particularly relevant during NAFLD and HCC, since the 
activities of these genes often link mechanistically the 
two conditions [24-26].  In a recent study, we observed 
that protein levels of macroH2A1.2, but not 
macroH2A1.1, are dramatically increased in the liver of 
the high-fat/diethynitrosamine diet and the genetic liver-
specific PTEN knock-out (KO) mice models of NAFLD 
[21], suggesting a differential functional role for these 
sister molecules in NAFLD pathogenesis. In this study 
we explore this hypothesis in vitro using two different 
hepatic cell lines, murine Hepa1-6 and human HepG2. 
We show that OAADPR-binding macroH2A1.1, but not 
macroH2A1.2, consistently ameliorates glucose 
metabolism and protects against lipid accumulation by 
altering the expression of genes involved in fatty acids 





MacroH2A1.1 protects Hepa1-6 and HepG2 cells 
from lipid accumulation 
 
MacroH2A1.2, but not of macroH2A1.1, is upregulated 
in the liver of NAFLD in vivo models [21]; however the 
function of these isoforms in NAFLD is unknown. We 
examined the effect of macroH2A1 isoforms on lipid 
accumulation in two well established hepatic cell lines, 
Hepa1-6 and HepG2 cells [26, 27]. HepG2 cells 
expressed more abundant endogenous levels of 
macroH2A1.1 and macroH2A1.2 than Hepa1-6 cells. 
(Figure 1B) However, within each cell line similar 
endogenous levels of macroH2A1.1 and macroH2A1.2 
were expressed (Figure 1B): this not being confounding 
factor, we ectopically over-expressed one or the other 
isoform. Transient transfection with cherry-tagged 
macroH2A1.1 or macroH2A1.2 constructs (Figure 1C, 
left) yielded a 30-40% efficiency (Figure 1C, right) and 
did not have any effect on the cell cycle, as measured by 
the percentage of cells gated in the G0/G1, S and G2/M 
phases by flow cytometry in Hepa1-6 cells (Table I, 
n=3). Similar results were obtained in HepG2 cells 
(data not shown). 24 hours post-trasfection Hepa1-6 and 
HepG2 cells were treated with a 100 μM 1:1 mixture of 
FFA (oleic acid and linoleic acid) for an additional 24 
hours, when cells were fixed and lipids were stained 
using ORO. Upon counterstaining with DAPI (blue), 
nuclei of Cherry-tagged macroH2A1.1 and 
macroH2A1.2 transfected cells were observed in 
pink/orange (Figures 2A and B). Morphometric 
evaluation of cytoplasmic ORO staining showed that 
macroH2A1.1-overexpressing Hepa 1-6 (Figure S1, left 
upper panels) or HepG2 (Figure 2, right upper panels) 
cells were protected from lipid accumulation as 
compared with control cells transfected with an empty 
vector, while macroH2A1.2-overexpressing cells only 
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slightly enhanced lipid content. In Hepa1-6 this trend 
was statistically significant in FFA-treated 
macroH2A1.1- or macroH2A1.2-overexpressing cells 
(Figure 2, lower left panel), while in HepG2 
significativity was obtained for FFA-treated 
macroH2A1.1-overexpressing cells (Figure 2, lower 
right panel). Intrahepatic lipid droplets as observed in 
NAFLD are constituted mainly of triglycerides (TG), 
synthesized upon FFA intake/synthesis and cholesteryl-
esters, which are instead synthesized upon augmented 
levels of free cholesterol. MacroH2A1.1-overexpressing 











































right panel) cells consistently displayed a decreased 
content of TG, compared to macroH2A1.2-
overexpressing and control cells. As for cholesterol 
content, macroH2A1.1-overexpressing Hepa1-6 and 
HepG2 cells showed a lower content when compared to 
control cells upon FFA exposure (Figure 1E). 
MacroH2A1.1 overexpressing HepG2 cells showed 
lower levels of cholesterol also in absence of FFA 
(Figure 1E). These data demonstrate for the first time 
that metabolite-binding histone variant macroH2A1.1, 
but not macroH2A1.2, protects against hepatic lipid 












































Figure  1.  (A)  Schematic  representation  of  the
structure  of  the  macroH2A1  gene,  which
contains  two  mutually  exclusive  exons
(macroH2A1.1  and  macroH2A1.2).  (B)  Histone
lysates were  isolated  from Hepa1‐6 and HepG2
cells  and  processed  for  immunoblotting.
Representative  images  for  macroH2A1.1,
macroH2A1.2  and  histone  H2A  are  shown.  (C)
Left: schematic representation of the constructs




Transient  over‐expression  of  cherry‐tagged
macroH2A1.1  or  macroH2A1.2  constructs  in
Hepa1‐6  cells. Nuclei were  counterstained with
DAPI.  In  the  overlay  image,  transfected  cells
overexpressing  macroH2A1.1  appear  in
pink/orange.  (D)  and  (E)  Triglyceride  and
cholesterol content  in Hepa1‐6 and HepG2 cells
cells  overexpressing macroH2A1  isoforms.  Cells
were  transfected  with  either  an  empty  vector
(control,  CTL)  or  with  Cherry‐tagged
macroH2A1.1  and  macroH2A1.1  constructs.  24
hours  later  cells  were  exposed  to  a  100  mM
mixture  of  FFA,  for  an  additional  24  hours.
Triglyceride (D) and cholesterol (E) content were
assayed  using  commercial  kits.  Results  are
expressed  as  percentage  of  controls,  means  ±
SEM of four independent experiments. *p<0.05.  
  
















































































































mixture  of  oleic  acid/linoleic  acid  (FFA)  conjugated with  albumin,  for  an  additional  24  hours.  Cells were  then  fixed,  nuclei




Cell cycle phase G0/G1 S G2/M 
 
Control (empty vector) 
 
        57.5 ± 3 
 
        18.7 ± 0.7 
 
         22.2 ± 0.2 
 
 
  macroH2A1.1 - Cherry 
 
 
        56 ± 0.8 
 
        19.3 ± 0.5 
 
         21.4 ± 2.5 
 
 
macroH2A1.2 - Cherry 
 
 
        57.1 ± 1.9 
 
        18.1 ± 0.7 
 
         22.8 ± 0.2 
 
  
www.impactaging.com                      38                                       AGING, January 2014, Vol. 6 No.1
MacroH2A1.1, but not macroH2A1.2, increases 
glycogen synthesis and glucose uptake in Hepa1-6 
and HepG2 cells 
 
Although there are a  few exceptions, generally insulin 
resistance is believed to be the primary cause of 
NAFLD [4]: insulin activates lipogenesis, accelerating 
FA synthesis and TG accumulation in the liver [28]. To 
determine if macroH2A1 isoforms do affect the 
hepatocyte response to insulin we analysed two insulin-
dependent mechanisms resulting in glucose storage and 
transport: glycogen synthesis and glucose uptake, 
respectively. To this purpose, we transiently transfected 
Hepa1-6 and HepG2 with macroH2A1.1 or 
macroH2A1.2 constructs. As shown in Figure 3A, 
consistent with previous data [26], insulin treatment (10-
7 M) induced an increase in glycogen storage in both 
cell lines. Strikingly, macroH2A1.1 overexpressing 
Hepa1-6 and HepG2 cells displayed an increase in 
glycogen content both in the absence and in the 
presence of insulin stimulation, while macroH2A1.2 
overexpression induced a decrease in glycogen 
synthesis specifically in Hepa1-6 but not in HepG2 
cells, where overexpression of macroH2A1.2 did not 
have an effect (Figure 3A and B). Measuring glucose 
uptake in Hepa1-6 and HepG2 cells that over-express 
either macroH2A1.1 or macroH2A1.2 we found that 
insulin-dependent glucose uptake was significantly 
enhanced in presence of macroH2A1.1 overexpression 


























H2A1.2 inhibited glucose uptake (Figure 3C and D). 
Altogether these data show that macroH2A1.1, but not 
macroH2A1.2 renders hepatocytes more sensitive to 
insulin, increasing glucose uptake and storage of 
glycogen, consistent with its effect on lipid 
accumulation (Figure 1 and 2).  
 
Control of genes involved in FA metabolism and of 
membrane lipid composition by macroH2A1 isoforms 
 
We examined the expression patterns associated with 
macroH2A1.1 or macroH2A1.2 over-expression of genes 
that may be involved in altered lipid and glucose 
metabolism in HepG2 and Hepa1-6 cells using a fatty 
liver array profiling the expression of, respectively, 84 
and 81 key genes involved in four key processes 
implicated in the development of NAFLD: carbohydrate 
metabolism, beta-oxidation, lipid metabolism/transport, 
and cholesterol metabolism transport. Both cell types 
were transfected with macroH2A1.1 or macroH2A1.2 
constructs and treated with FFA. We then inferred the 
best clustering from our qRT-PCR gene expression data  
by using a multiscale bootstrap resampling: this 
partitioning method ensures the representation of the 
most significant differences between genes belonging to 
different clusters (Figure 4 and S1). Hepa1-6 exhibit a 
greater variability in gene expression when overexpres-
sing macroH2A1.1 or macroH2A1.2 in the presence of 


























Figure  3.  Overexpression  of  macroH2A1  isoforms
(macroH2A1.1  or  macroH2A1.2)  and  glycogen
synthesis (A) and glucose uptake (B) content in Hepa1‐
6  and  HepG2  cells.  A,  B:  cells  were  transiently
transfected  as  described  in  the  legends  of  Figure  2.
Glycogen  content  (A)  and  glucose  uptake  (B)  were
assessed by  stimulation with 10‐7 mol/L  insulin, using
[3‐3H]‐glucose  incorporation  and  2‐deoxy‐D‐[2,6‐3H]‐
glucose uptake, respectively. Results are expressed as
percentage  of  controls,  means  ±  SEM  of  four
independent experiments. *p<0.05.  
  






































Moreover, data were clustered in undirected graphs, 
representing the above mentioned four processes of 
carbohydrate metabolism, beta-oxidation, lipid 
metabolism/transport, and cholesterol metabolism 
transport, where the thickness of the edges between 
genes correspond to the different degree of reliability of 
interaction, based on a number of heterogeneous data 
sources (protein domains, co-expression, co-
localization, genetic interactions, pathways, physical 
and predicted interactions) (Figure 5A-D, S2A-D). In 
Hepa1-6, macroH2A1.1 over-expression induced, upon 
FFA treatment, dramatic changes in the expression of 
genes involved in carbohydrate metabolism when 
compared to macroH2A1.2 (downregulation of G6PC, 
GCK, MLXIPL, PDK4 and RBP4 and upregulation of 
PCK2 and GSK3B) or to FFA condition (upregulation 
of G6PC, GCK, MLXIPL and GSK3B and down-






































In Hepa1-6 cells, macroH2A1.1 or macroH2A1.2 
overexpression altered in opposite directions the 
expression of carnitine palmitoyltransferases, and 
mTOR, among others, in the beta-oxidation pathway 
(Figure 5B). Hepa1-6 overexpressing macroH2A1.1 
also displayed a decreased expression of genes involved 
in fatty acid synthesis/transport (SCD1, FASN, LPL 
among others) and of genes involved in the metabolism 
and transport of cholesterol (CYP2E1, CD36, PPARG, 
SREBF1, APOB, LDLR, HMGCR and SREBF2, among 
others) when compared to overexpressing 
macroH2A1.2, upon FFA treatment (Figure 5C and D). 
In contrast to the dramatic changes observed in Hepa1-6 
cells, macroH2A1.1 overexpressing HepG2 cells with 
downregulation of RBP4, FASN, LPL and SCD1 
displayed very few changes in gene expression when 
compared to macroH2A1.2 overexpressing cells, a 
result similar to what was observed with Hepa1-6 cells 
Figure 4. Heatmap and clusters of gene expression of Hepa1‐6 cells overexpressing macroH2A1.1 (m1.1) or macroH2A1.2 (m1.2)
and treated with FFA. Results are expressed as ratio of FFA‐treated versus untreated cells. Optimal clusters have been computed by
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(Figure S2A-D). Therefore, one can conclude that 
macroH2A1.1 and trigger a distinct pattern of 
expression of genes involved in lipid metabolism. It is 
worth noting that two key genes found downregulated 
upon macroH2A1.1 compared to macroH2A1.2 
overexpression in both cell types analyzed are stearoyl-
CoA desaturase 1 (SCD1) and fatty acid synthase 
(FASN), enzymes that catalyze rate-limiting steps in the 
desaturation of FA and in the de novo biogenesis of FA, 
respectively, and shift lipid turnover towards increased 
lipogenesis in the elderly [29].  We thus hypothesized 
that macroH2A1 isoforms could differently modulate 
cellular membrane lipid composition: macroH2A1.1 or 









































fection in Hepa1-6 and HepG2 cells, and subsequently 
treated with FFA. Cell pellets were then processed for 
thin layer chromatography (TLC) and transesteri-
fication procedures to identify levels of total 
unsaturated fatty acids (UFA) [30]. As shown in 
Figure S3, in both HepG2 and Hepa1-6 cells 
macroH2A1.1 induced a decrease (~60 and 50%, 
respectively) in UFA content when compared with 
their respective untreated control cells, while 
macroH2A1.2 only slightly decreased the levels of 
UFA in HepG2 but increased them of about two fold 
in Hepa1-6 cells. These data demonstrate that 
macroH2A1.1 consistently decreases the formation of 









































Figure 5. Differential effects of macroH2A1.1  and macroH2A1.2 on  the expression of  genes  involved  in  lipid  and
carbohydrate metabolism  in Hepa1‐6  cells.  84  genes  contained  in  a  commercially  available  fatty  liver  array were
measured by qRT‐PCR  in Hepa1‐6 cells  transiently  transfected and  treated with FFA, as described  in  the  legends of
Figures 1 and 2. Results were clustered in four functional processes (carbohydrate metabolism, A; beta‐oxidation, B;
lipid metabolism, C;  cholesterol  transport, D), built  on  a number of  complementary  system  analyses of biological
pathways (see Supplemental Materials and Methods). Results of gene expression in each histogram are represented
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DISCUSSION 
 
In this study we report that the two exon splicing 
isoforms of macroH2A1 (macroH2A1.1 and 
macroH2A1.2), a histone variant functioning as a 
gatekeeper of cell fate and proliferation in various cell 
types [9-11, 31, 32], have opposite effects on the 
development of fat accumulation in hepatocytes. When 
compared with macroH2A1.2, macroH2A1.1 has a 
subtle structural difference that determines its tight 
binding to NAD+ metabolites produced by PARP1 and 
SIRT1 [14], two crucial enzymes involved in healthspan 
[33, 34]. We previously found that in the liver of mice 
models with NAFLD, macroH2A1.2 protein is 
upregulated whereas macroH2A1.1 levels do not 
change [21]. In the current study we found that in both 
human and murine cell lines (HepG2 and Hepa1-6, 
respectively) macroH2A1.1 overexpression, but not 
macroH2A1.2, protected from triglyceride and 
cholesterol accumulation, and sensitized cells to the 
action of insulin, inducing glucose uptake and 
gluconeogenesis. The observed slightly detrimental 
effect of macroH2A1.2 overexpression on lipid and 
glucose metabolism in vitro is consistent with the 
upregulation of macroH2A1.2 observed in vivo [21]; 
however it is not known if this upregulation of 
macroH2A1.2 observed in the livers of mice models of 
NAFLD is consequent to lipid accumulation or to other 
disease factors (oxidative stress, inflammation) that in 
turn could trigger NAFLD causatively through 
macroH2A1.2 upregulation. Further studies are 
warranted to elucidate the role of macroH2A1.2 in the 
“multi-hit” origin of NAFLD development. Recent 
advances in our understanding of the mechanisms 
regulating macroH2A1 alternative splicing [18, 35] are 
not helpful to understand in response to which stimuli 
the protein levels of the isoforms change in the liver. In 
fact mRNA levels for both macroH2A1.1 and 
macroH2A1.2 in NAFLD mice models and in liver 
biopsies from patients were variable and did not reflect 
the differences observed in the protein levels found in 
NAFLD and HCC [18, 21]. NAFLD is a serious risk 
factor for the development of advanced liver injury, 
such as steatohepatitis and HCC. MacroH2A1.1 but not 
macroH2A1.2 protects against the occurrence of various 
human cancers, influencing pathogenesis and/or 
survival [19, 20, 23]. Whether this is true for NAFLD-
associated HCC remains to be elucidated. Our gene 
expression analysis, covering a large array of players 
involved in lipid metabolism, showed dramatic changes 
in Hepa1-6 overexpressing macroH2A1.1 as compared 
to macroH2A1.2 overexpressing cells in the presence of 
FFA, which were less accentuated in HepG2 cells. 
These profound changes in Hepa1-6 corroborate an 
anti-lipidogenic role for macroH2A1.1 as compared to 
macroH2A1.2. It remains to be explained why on the 
one hand similar effects of macroH2A1 isoforms on 
lipid accumulation and glucose metabolism were 
observed in Hepa1-6 and HepG2 cells, while on the 
other hand a different magnitude of impact on gene 
expression was observed in the two cell types. This 
could likely reflect species-specific (mouse versus 
human) and different levels of endogenous macroH2A1 
isoforms expression (Figure 1) between the two cell 
models. Nevertheless, upon FFA treatment we observed 
a downregulation of SCD1 and FASN upon 
macroH2A1.1- as compared to macroH2A1.2-
overexpression, in both Hepa1-6 and HepG2 cells. Low 
levels of SCD1 and FASN expression are protective 
against obesity, insulin resistance and NAFLD [36, 37].  
Our membrane lipid profile assay showed an overall 
increase in membrane unsaturated FA, which could be 
related functionally to an increasing expression/activity 
of these enzymes. The profound differences, caused by 
a few amino acid discrepancy between macroH2A1.1 
and macroH2A1.2 isoforms, in gene expression and 
lipid metabolism in the liver are remarkable. In this 
respect, the property whereby macroH2A1.1 binds with 
very tight affinity with OAADPR produced by SIRT1 is 
intriguing, considering that the activation of these 
enzymes is considered protective against NAFLD 
favouring a overall healthy aging [38], and is under 
scrutiny for drug design [39, 40].  
 
Interestingly, OAADPR can be bound and deacetylated 
by the macrodomain contained in proteins displaying 
different functions and participating to distinct pathways 
other than macroH2A1, suggesting an evolutionary 
conserved molecular affinity [41]. OAADPR and 
macroH2A1 have been independently reported to 
regulate gene silencing and the gating of members of the 
large superfamily of transient receptor potential (TRP) 
ion channels [42, 43]. Of note, macroH2A1.1 suppresses 
growth of cancer cells in a manner dependent on its 
ability to bind NAD+ metabolites such as OAADPR 
[18]. Whether this property plays a role in liver diseases 
and more broadly in healthy aging is unknown. The 
presence of a metabolite-binding function in a chromatin 
component opens new potential connections between 
gene expression and lipid metabolism in the liver, which 
warrants further structural and functional studies. Macro 
domains could also represent attractive and novel drug 
targets, likely in connection to the well-established 




Cell cultures, constructs, transfection, treatment and 
imaging. Both Hepa1-6 and HepG2 hepatoma cells (of 
mouse and human origin, respectively) were cultured in 
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Dulbecco’s MEM supplemented with 10% fetal bovine 
serum (FBS), 2mM L-Glutamine and 100U 
penicillin/streptomycin mix as previously described [26, 
27]. Cells were passaged every 3-4 days and cultured in 
6 wells plates for imaging experiments. For treatment 
with free fatty acids, cells were exposed 24 hours to a 
mixture of albumin conjugated oleic acid and linoleic 
acid (OA/LA, Sigma) to a final concentration of 100 
μM. Constructs for macroH2A1.1 and macroH2A1.2 
were previously described [16, 44]. Transient 
transfections were performed using Lipofectamine 
reagent (Invitrogen), according to manufacturer’s 
instructions. Oil Red O (ORO) staining of lipid droplets 
was performed as previously described [26]. 
Fluorescent images were taken on a Nikon Eclipse 
TE200 inverted fluorescent microscope, using a U-III 
advanced exposure system with Multi-point sensor, and 
a Nikon FDX-35 camera. Filters used were i) G-2A; 
Ex510-560; DM 575; BA590 (Red); ii) UV-2A; Ex 
330-380; DM 400; BA 420 (Dapi): Dapi-Fitc-
Rhodamine (Cherry and merge). Software ImageJ 
(NIH) was used to quantify ORO-stained lipid droplets 
in individual Hepa1-6 or HepG2 cells [26]. 
 
Cell cycle analysis. Cells were harvested at least 3 hours 
before the experiment and fixed with 1ml of 70% cold 
ethanol at -20°C, as indicated by the Muse Cell Cycle 
Kit User’s Guide. 200 µl of ethanol-fixed cells were 
washed in PBS and stained with the Muse Cell Cycle 
Reagent containing propidium iodide and RNAse A for 
30 minutes at room temperature,  before loading on 
Muse Cell Analyzer (Millipore, Italy) according to the 
supplied staining protocol. 
 
Histone acid extraction and immunoblotting from 
cultured cells. Histone fraction was enriched using an 
acid extraction protocol. Briefly, cell pellets were 
suspended and homogenized in 200 µl of H-lysis 
solution (0.2 M sucrose, 3 mM CaCl2, 1 mM Tris-HCl 
pH8.0, 0.5 NP40, protease inhibitor cocktail), incubated 
on ice for 8 min, and centrifuged at 1,300×g, 4°C, for 5 
min to separate supernatant from nuclei fraction (P1). 
P1 was washed once with H-wash solution (300 mM 
NaCl, 5 mg MgCl2, 5 mM DTT, 0.5% NP40) and lysed 
for 30 min in 100 µl H-extract solution (0.5 mM HCl, 
10% glycerol, protease inhibitor cocktail), followed by 
centrifugation at 13,000×g 4°C, for 5 min. Finally, TCA 
precipitation was performed. Equal amounts of protein 
were separated by SDS-PAGE, transferred to PVDF 
membrane (Amersham,  Buckinghamshire, UK) and the 
resulting immune-complex was visualized using the 
molecular imager ChemiDoc XRS + system (Bio-Rad). 
Densitometry was performed using Image Lab Software 
(Bio-Rad). Primary antibodies for MacroH2A1.1 and 
MacroH2A1.2 were generated at the European 
Molecular Biology Laboratory (EMBL) and were a 
courtesy of Prof. Andreas Ladurner (Ludwig 
Maximilian University, LMU, Munich, Germany). 
Antibodies against histone H2A (Cell Signaling) were 
used to normalize protein levels. 
 
Triglyceride and cholesterol measurement in cell 
cultures. Lipids were extracted as previously described 
[26]. Intracellular triglycerides (TG) were quantified 
with the commercially available triglyceride glycerol 
phosphate oxidase-paminophenazone (GPO-PAP) kit 
(Roche), while cholesterol was detected using the 
cholesterol quantitation kit (Calbiochem), respectively. 
 
Glycogen synthesis and glucose uptake assays. 
Glycogen synthesis in Hepa1-6 and HepG2 cells was 
assessed by measuring [3-3H]-glucose incorporation per 
microgram of protein as previously described [45]. 
Measurements of 2-deoxy-D-[2,6-3H]-glucose uptake 
by Hepa1-6 and HepG2 cells were performed as 
previously described [46]. Non-specific glucose uptake 
was determined in the presence of 10 mM cytochalasin 
B. Cell-associated radioactivity was measured by liquid 
scintillation counting in a β-counter (Wallac 1409, 
Perkin Elmer). 
 
RNA extraction and Fatty Liver Array profile. Total 
RNA was isolated using the RNeasy Mini Kit (Qiagen, 
Milan, Italy) and subsequently treated with 
deoxyribonuclease I. Human and Fatty Liver RT² 
Profiler™ PCR Array profiles were then assessed 
following the manufactures protocol (SABioscience, 
Milan, Italy). Reactions were set up in 96-well plates 
using a 7700HT Real-Time PCR System (Applied 
Biosystems, Foster City, CA), Optical data obtained 
were analyzed using the default and variable parameters 
available in the SDS software package (version 1.9.1; 
Applied Biosystems, Foster City, CA). 
 
System biology analyses of gene expression. Heatmaps 
and clusters have been calculated and drawn by R 
framework, ver. 2.15.2. Optimal clusters have been 
computed by pvclust [47], an R package for assessing 
the uncertainty in hierarchical cluster analysis. For each 
cluster in hierarchical clustering, significance levels 
have been calculated via multiscale bootstrap 
resampling. The lower p-value of a cluster, the stronger 
the support of the data to the cluster. Interactions 
between genes participating to the carbohydrate 
metabolism, beta-oxidation, cholesterol metabolism/ 
transport and other lipid metabolism/transport processes 
were reconstructed both for Hepa1-6 and HepG2 cells. 
Four hypergraphs per cell type were then built on a 
number of heterogeneous data sources: protein domains 
(Interpro and PFAM), co-expression (curated literature 
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and Gene Expression Omnibus), co-localization (Gene 
Expression Omnibus), genetic interactions (BIOGRID 
and IREF), pathways (PathwayCommons, IMID, NCI 
NATURE, REACTOME, KEGG and BIOCARTA), 
physical interactions (BIOGRID, BIND, HPRD, 
INTACT, MINT, MPPI and OPHID) and predicted 
interactions (curated literature). Any two genes were 
connected by an edge, whenever at least an interaction 
evidence of any of the abovementioned interaction 
categories was found. Several pairs of genes resulted to 
be connected by more than one edge. Each hypergraph 
was weighted and signed. Weights over the edges 
represented the reliability of the corresponding 
interactions and were proportional to the thickness of 
the edges. Gene expressions for cells transfected with 
macroH2A1.1 or macroH2A1.2 constructs with or 
without exposure to FAs were represented with 
histograms. Each hypergraph was deterministically 
transformed into an undirected graph by applying an 
injective function to the sets of weights over the edges. 





௜ୀଵ  where n is the 
number of edges connecting any two nodes A and B and 
i refers to the ith edge, takes the weights of the edges 
connecting any two nodes in input and gives a unique 
value in output. Constitutively, it gives more and more 
importance to the genes that are connected by multiple 
edges.  
 
Lipidomic. Cells were thoroughly washed with 
phosphate buffer, added with water and pelleted by 
centrifugation at 14,000 g for 40 min at 4°C. The pellet 
was resuspended in pure water and centrifuged, then 
was dissolved in 2:1 chloroform:methanol and 
examined by thin layer chromatography (TLC using a 
bidimensional system; first eluent: chloroform: 
methanol:acetic acid:water 55:33:9:3; second eluent: 
hexane:diethyl ether:acetic acid 30:29:1) to determine 
the purity of the phospholipid fraction. The 
phospholipid extract was then treated with 0.5 M 
KOH/MeOH for 10 min at room temperature to convert 
the fatty acid residues of the phospholipids into their 
corresponding fatty acid methyl esters (FAMEs). After 
this transesterification step, FAMEs were extracted with 
n-hexane, and analyzed by gas chromatography. 
Geometrical trans unsaturated fatty acids were 
identified by comparison with standard references 
obtained by synthesis, as described [30]. 
 
Statistical analysis. Results are expressed as means ± 
SEM. Comparisons between groups were performed 
using a Student’s t-test with non-parametric Mann-
Whitney test using GraphPad Prism Software (version 
5.00 for Windows, San Diego, CA, USA): a p-value ≤ 
0.05 was considered significant. 
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or  macroH2A1.2  (m1.2)  and  treated  with  FFA.  Results  are  expressed  as  ratio  of  FFA‐treated  versus  untreated  cells.
Optimal  clusters  have  been  computed  by  the  pvclust  method.  Results  were  grouped  in  four  functional  processes




















































1 and 2. Results were clustered  in  four  functional hypergraphs  (carbohydrate metabolism, A; beta‐oxidation, B;  lipid
metabolism/transport, C; cholesterol transport/metabolism, D), built on a number of complementary system analyses
of biological pathways, as described  in  the Supplemental Material & Methods  section. Results of gene expression  in
each histogram are represented as % of FFA‐treated mock‐transfected (blue), FFA‐treated macroH2A1.1‐overexpressing
(green) or FFA‐treated macroH2A1.2 – overexpressing  (red)  condition  related  to  their  respective untreated  controls.
Results are expressed as percentage of controls, means ± SEM of two independent experiments. *p<0.05. 
Supplemental  Figure  3.  Overexpression  of 
macroH2A1  isoforms  (macroH2A1.1  or  macroH2A1.2) 
and  trans  unsaturated  fatty  acids  in  Hepa1‐6  and 
HepG2 cells. A, B: cells were transiently transfected and 
treated with FFA as described in the legends of Figure 1 
and  2.  Trans  unsaturated  fatty  acids  content  was 
measured using TLC‐chromatography in HepG2 (A) and 
Hepa1‐6 (B) upon FFA treatment. Results are expressed 
as  percentage  of  respective  controls  (untreated 
macroH2A1.1‐  or  macroH2A1.2‐overexpressing  cells), 
and are means of two independent experiments. 
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